ZYKADIA
PeakNDAORALCAPSULEPriority Review
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYKADIA (ceritinib) is an oral small-molecule ALK inhibitor approved by the FDA in April 2014 for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It works by inhibiting anaplastic lymphoma kinase (ALK) and demonstrates activity against crizotinib-resistant ALK mutations, making it a second-generation option in the ALK inhibitor class.
Peak5.7 years to LOE
Peak lifecycle indicates a mature brand with stable commercial operations and established field infrastructure supporting the ALK-positive NSCLC patient population.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZYKADIA provides exposure to specialty oncology commercial operations and ALK-positive NSCLC patient advocacy networks. This peak-stage product offers stability with established sales infrastructure, though limited new trial recruitment suggests fewer clinical development career opportunities.
Brand ManagerMedical Science Liaison
Worked on ZYKADIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.